NewAmsterdam Pharma (NAMS) Total Non-Current Liabilities (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Total Non-Current Liabilities data on file, last reported at $20.9 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 9.67% year-over-year to $20.9 million; the trailing twelve-month figure through Mar 2026 stood at $20.9 million (up 9.67% YoY), and the FY2025 full-year result was $32.4 million, down 69.05% from the prior year.
• Total Non-Current Liabilities retreated to $20.9 million in Q1 2026, from $32.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $104.7 million in Q4 2024 to a low of $11432.6 in Q2 2023.
• A 5-year average of $35.1 million and a median of $26.6 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 401006.76% in 2024 and slumped 69.05% in 2025, its largest moves.
• Tracing NAMS's Total Non-Current Liabilities over 5 years: stood at $11.8 million in 2022, then surged by 330.18% to $50.9 million in 2023, then soared by 105.71% to $104.7 million in 2024, then tumbled by 69.05% to $32.4 million in 2025, then sank by 35.64% to $20.9 million in 2026.
• Business Quant data shows NAMS's Total Non-Current Liabilities at $20.9 million in Q1 2026, $32.4 million in Q4 2025, and $16.9 million in Q3 2025.